Shrier Wealth Management LLC Makes New $828,000 Investment in Amgen Inc. $AMGN

Shrier Wealth Management LLC acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,529 shares of the medical research company’s stock, valued at approximately $828,000.

Several other hedge funds also recently modified their holdings of the stock. Board of the Pension Protection Fund bought a new stake in Amgen during the fourth quarter worth about $26,000. Olistico Wealth LLC bought a new position in Amgen in the fourth quarter valued at approximately $33,000. Holos Integrated Wealth LLC acquired a new position in shares of Amgen during the 4th quarter worth approximately $37,000. Howard Hughes Medical Institute acquired a new position in shares of Amgen during the 2nd quarter worth approximately $32,000. Finally, Cloud Capital Management LLC bought a new stake in shares of Amgen during the 3rd quarter worth approximately $34,000. Institutional investors own 76.50% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive cardiovascular data for Amgen’s Repatha: a trial showed a 31% reduction in first major cardiovascular events in a high?risk population without known significant atherosclerosis — a tailwind for Repatha’s commercial outlook and long?term revenue potential. Amgen: Repatha Cuts Risk…
• Positive Sentiment: High?profile media/analyst praise has supported sentiment — Jim Cramer noted Amgen as an attractive large?cap biotech holding, and Zacks highlighted Amgen’s resilient drug portfolio as offsetting industry headwinds. Those endorsements can boost short?term demand. Amgen (AMGN) Stock Up Since Jim Cramer Said…
• Positive Sentiment: Zacks analyst commentary reiterates AMGN’s upside from a diversified drug portfolio and steady cash flows, supporting the stock amid sector volatility. The Zacks Analyst Blog Roche Holding, AT&T and Amgen
• Neutral Sentiment: Sector news (other biotech trial readouts and IPO activity) is driving broader health?care flows but is not specific to Amgen’s fundamentals; watch market?wide risk appetite. Viridian tumbles on positive data for key eye drug prospect
• Negative Sentiment: FDA safety warning on Tavneos (Amgen’s drug for certain rare autoimmune diseases): regulators identified dozens of drug?induced liver injury cases (reports cite ~76 cases) and urged close monitoring and prompt discontinuation if liver damage is suspected — a material safety/regulatory overhang that could affect prescribing, labeling, and long?term sales. US FDA warns of liver injury cases tied to Amgen’s rare disease drug
• Negative Sentiment: Competitive pressure: Teva’s FDA approval of a Prolia (denosumab) biosimilar and other biosimilar filings increase competition in bone?health markets, which could weigh on Amgen’s Prolia pricing and market share over time. TEVA’s Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on AMGN shares. Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. Piper Sandler upped their price target on shares of Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Rothschild & Co Redburn increased their price target on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. Cantor Fitzgerald lifted their price objective on shares of Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. Finally, TD Cowen restated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $354.60.

Amgen Stock Up 0.8%

Amgen stock opened at $351.85 on Wednesday. The company’s 50-day moving average price is $363.37 and its two-hundred day moving average price is $331.58. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The stock has a market cap of $189.67 billion, a P/E ratio of 24.73, a P/E/G ratio of 3.46 and a beta of 0.45. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is currently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.